Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Maintains Neutral on Codiak BioSciences, Lowers Price Target to $1.4

Goldman Sachs analyst Andrea Tan maintains Codiak BioSciences (NASDAQ:CDAK) with a Neutral and lowers the price target from $2 to $1.4.
byBenzinga Newsdesk
November 7, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Andrea Tan maintains Codiak BioSciences (NASDAQ:CDAK) with a Neutral and lowers the price target from $2 to $1.4.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0